In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dova Pharmaceuticals Inc.

Division of Swedish Orphan Biovitrum AB
www.dova.com

Latest From Dova Pharmaceuticals Inc.

Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs

A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma. 

Financing Deals

UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears

The deal, welcomed by analysts, means that the Belgian drug maker has two late-stage products for the rare disease myasthenia gravis to challenge Alexion's Soliris.
M & A Companies

Sobi Targets Thrombocytopenia In $915m Swoop For Dova

The Swedish group has got hold of the ITP and CLD drug Doptelet, widening its hematology business beyond hemophilia.

M & A Blood & Coagulation Disorders

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances now includes four new products, one of which is Regeneron Pharmaceuticals/Sanofi’s Libtayo (cemiplimab) for treating advanced cutaneous squamous cell carcinoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

Approvals Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Swedish Orphan Biovitrum AB
  • Senior Management
  • David Zaccardelli, Pres. & CEO
    Mark W Hahn, CFO
    Lee Allen, CMO
    Jason Hoitt, Chief Commercial Officer
  • Contact Info
  • Dova Pharmaceuticals Inc.
    Phone: (844) 506-3682
    240 Leigh Farm Rd., Ste. 245
    Durham, NC 27707
    USA
UsernamePublicRestriction

Register